Back to Agenda
Exploration of Metabolic Diseases: Is the Liver the New Heart?
Session Chair(s)
Clayton Dehn, MS
Vice President, Clinical Pharmacology Services, High Point Clinical Trials , United States
With the increasing prevalence of metabolic disease, this session will explore the rising incidence of metabolic disease such as diabetes as well as emerging areas of metabolic diseases such as NAFLD/NASH. With new imaging technique enhancements, we observe previously undetected liver scarring progressing to fibrosis and onto cirrhosis. With no NAFLD/NASH-specific treatment to date, the FDA has provided recommendations in this indication.
Learning Objective : Discuss why liver fibrosis is becoming a concern in the pharmaceutical industry and is an area needed for therapy.
Speaker(s)
Liver Let Die: Challenges and Opportunities in Developing Early Interventions for Fatty Liver Disease
Vice President, Clinical Pharmacology Services, High Point Clinical Trials , United States
Understanding the Natural History and Health Burden of Nonalcoholic Fatty Liver Disease (NAFLD): America’s Newest Epidemic
Director of the Metabolic Center, Texas Liver Institute, United States
Challenges and Opportunities in Clinical Development in Non-Alcoholic Steatohepatitis (NASH): Drugs for NASH Paving the Way
Executive medical director, Covance Inc., United Kingdom
The DASH to Treat NASH
Global Development Lead, NASH, Shire, United States
Have an account?